JAGX Would you buy something that was 10000x more expensive?
Jaguar Health, Inc. is a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide.
July 20, 2020 : Jaguar Health, Inc. announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine the second-to-last required technical section to support approval of Jaguar's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea in dogs, although this filing was originally scheduled for submission by the end of August 2020.
More than 230,000 dogs in the U.S. receive chemotherapy treatment for various cancers each year, and roughly one in four (more than 50,000 dogs) will experience diarrhea as a side effect of treatment.
OASIS CAPITAL LLC REPORTS 9.99% PASSIVE STAKE IN JAGUAR HEALTH AS OF JULY 7- SEC FILING
Net Income $-38,540,000
Market Cap $42.15 million
Annual Sales $5.78 million
Debt-to-Equity Ratio 0.08
JAGX is a risky bet that can double your money in seconds.
Not trading advice.
If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
July 20, 2020 : Jaguar Health, Inc. announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine the second-to-last required technical section to support approval of Jaguar's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea in dogs, although this filing was originally scheduled for submission by the end of August 2020.
More than 230,000 dogs in the U.S. receive chemotherapy treatment for various cancers each year, and roughly one in four (more than 50,000 dogs) will experience diarrhea as a side effect of treatment.
OASIS CAPITAL LLC REPORTS 9.99% PASSIVE STAKE IN JAGUAR HEALTH AS OF JULY 7- SEC FILING
Net Income $-38,540,000
Market Cap $42.15 million
Annual Sales $5.78 million
Debt-to-Equity Ratio 0.08
JAGX is a risky bet that can double your money in seconds.
Not trading advice.
If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
Private Signals patreon.com/PremiumOptionsSignals
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.